Focus: Immunai is an AI-driven biotechnology company specializing in immune system mapping, leveraging computational biology to understand and target immune mechanisms. The company operates at scale with 5,000+ employees as a publicly traded entity.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
No open roles listed right now. Follow Immunai to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
No open positions listed yet. Check their careers page directly.
Help build intelligence for Immunai
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Immunai's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Dose-dependent IFN programs in myeloid cells after mRNA and adenovirus COVID-19 vaccination.
Long-term remission after cilta-cel in multiple myeloma is linked to diverse T cells and low myeloid suppression.
Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy.
Systematic benchmarking of imaging spatial transcriptomics platforms in FFPE tissues.
Type 2 immune responses are associated with less severe COVID-19 in a hospitalized cohort.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo